ArticleHepatology international2026
Inhibition of the U12-type splicing factor ZCRB1 mediates retention of the USP21 minor intron to suppress malignant progression in hepatocellular carcinoma.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Crosstalk between alternative splicing and non-coding RNAs in hepatocellular carcinoma: from regulatory mechanism to therapeutic implications.Non-coding RNA research · 2026Review
- Loss of U11/U12 spliceosome geneLife science alliance · 2026Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
backgroundRNA splicing dysregulation plays an important role in hepatocellular carcinoma (HCC). However, the critical functions of zinc finger CCHC type and RNA binding motif 1 (ZCRB1), one of the key components of the minor spliceosome, in HCC remains unclear.
methodsThe mRNA and protein expression of ZCRB1 were evaluated by bioinformatics analysis, western blotting and immunohistochemistry. The role of ZCRB1 on biological functions of HCC were measured in vitro and in vivo. rMATS software analyzes RNA-seq data to identify ZCRB1-related alternative splicing (AS) events. Therapeutic targeting of ZCRB1 using GalNAc-conjugated small-interfering RNA was investigated in the HCC mouse model.
resultsWe discovered that ZCRB1 was dramatically upregulated in HCC tissues, and high ZCRB1 expression was associated with poor prognosis in HCC patients. Knockdown of ZCRB1 significantly reduced HCC cell proliferation and promoted cell apoptosis. In addition, high enrichment levels of H3K27ac in the promoter region activated ZCRB1 expression. Mechanistically, AS event analysis revealed that knockdown ZCRB1 resulted in retention of intron 11 of USP21 thereby reducing USP21 expression. USP21 overexpression partially rescued the attenuation of malignant behavior of HCC cells caused by inhibition of ZCRB1, and inhibition of USP21 reduced proliferation in HCC cells. Furthermore, therapeutic targeting of ZCRB1 using GalNAc-conjugated small-interfering RNA significantly reduced tumor burden and increased the infiltration level of CD8+ T cells in the HCC mouse model.
conclusionsThis study identified ZCRB1 as an oncogenic U12-type splicing factor that supports malignant growth through blocking intron 11 retention of USP21 in HCC cells. Thus, ZCRB1 could serve as a new target for HCC therapy and a potential biomarker for HCC prognosis.
Indexed as
Identifiers
41258964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.